Murdo Ferguson
Dalhousie University
16 Papers
38 Citations
Murdo Ferguson is an academic researcher from Dalhousie University. The author has contributed to research in topics: Vaccination & Medicine. The author has an hindex of 9, co-authored 16 publications.
Chat about Author
Papers
Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study.
Barbara Romanowski,Tino F. Schwarz,Linda Ferguson,Murdo Ferguson,Klaus Peters,Marc Dionne,Karin Schulze,Brian Ramjattan,Peter Hillemanns,Ulrich Behre,P.V. Suryakiran,Florence Thomas,Frank Struyf +12 more
TL;DR: Investigation of the immunogenicity and safety of 2-dose schedules of the HPV-16/18 AS04-adjuvanted vaccine found that a 2D schedule could facilitate implementation of HPV vaccination programs and improve vaccine coverage and series completion rates.
111
The Adjuvanted Recombinant Zoster Vaccine Confers Long-term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase III Clinical Trials (ZOE-50 and ZOE-70).
Céline Boutry,Andrew Hastie,Javier Díez-Domingo,Juan Carlos Tinoco,Chong-Jen Yu,Charles P. Andrews,Jean Beytout,Covadonga Caso,Huey-Shinn Cheng,Hee Jin Cheong,Eun Ju Choo,Dan Curiac,Emmanuel Di Paolo,Marc Dionne,Tamara Eckermann,Meral Esen,Murdo Ferguson,Wayne Ghesquiere,Shinn-Jang Hwang,Shinn-Jang Hwang,Thiago Junqueira Avelino-Silva,Pavel Kosina,Chiu-Shong Liu,Jukka Markkula,Beate Moeckesch,Cláudia Murta de Oliveira,Dae Won Park,Karlis Pauksens,Paola Pirrotta,Georg Plassmann,Carol Pretswell,Lars Rombo,Bruno Salaun,Johan Berglund,Isabelle Schenkenberger,Tino F. Schwarz,Meng Shi,Benita Ukkonen,Toufik Zahaf,Cristiano Zerbini,Anne Schuind,Anthony L. Cunningham +41 more
TL;DR: In this paper, an ongoing follow-up study (NCT02723773) evaluating persistence of efficacy and immune responses for six additional years in adults vaccinated with the glycoprotein E (gE)-based adjuvanted recombinant zoster vaccine (RZV) at ≥50 years of age in two pivotal efficacy trials (ZOE-50/70).
57
Safety and Long-term Humoral Immune Response in Adults After Vaccination With an H1N1 2009 Pandemic Influenza Vaccine With or Without AS03 Adjuvant
Murdo Ferguson,George Risi,Matthew Davis,Eric Sheldon,Mira Baron,Ping Li,Miguel Madariaga,Louis Fries,Olivier Godeaux,David W. Vaughn +9 more
TL;DR: A single dose of the 3.75-μg HA AS03(A)-adjuvanted H1N1 2009 influenza vaccine was highly immunogenic in both age strata (18-64 and >64 years), inducing long-term persistence of the immune response until at least 6 months after dose 1.
Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults
Anuradha Madan,Nathan Segall,Murdo Ferguson,Louise Frenette,Robin Kroll,Damien Friel,Jyoti Soni,Ping Li,Bruce L. Innis,Anne Schuind +9 more
TL;DR: Two doses of AS03-adjuvanted H7N9 vaccine were well tolerated and induced a robust antibody response at antigen-sparing doses in healthy adults and met regulatory acceptance criteria.
42
Prospective clinical trial of hepatitis B vaccination in adults with and without type-2 diabetes mellitus
Olivier Van Der Meeren,James T. Peterson,Marc Dionne,Richard Beasley,Peter R. Ebeling,Murdo Ferguson,Michael D. Nissen,Paul Rheault,Richard Rw Simpson,Marc De Ridder,Priya Diana Crasta,Jacqueline M. Miller,Andrew Af Trofa +12 more
TL;DR: Hepatitis B vaccine is immunogenic in patients with diabetes and has a similar safety profile to vaccination in healthy controls, and hepatitis B vaccine should be administered as soon as possible after the diagnosis of diabetes.
28